DEF 14A: Harrow, Inc. Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Harrow, Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 14, 2024, outlining proposals for director elections, auditor ratification, and executive compensation advisory vote.

Summary

• Harrow, Inc. will hold its 2024 Annual Meeting of Stockholders on June 14, 2024, at 8:00 a.m. Central Time, at the company's corporate office in Nashville, TN.
• Stockholders of record as of April 16, 2024, are entitled to vote at the meeting.
• The meeting will address the election of five director nominees, ratification of KMJ Corbin & Company LLP (or its successor) as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on the compensation of the company's named executive officers.
• The Board of Directors recommends voting for the election of all director nominees, for the ratification of the selection of KMJ Corbin & Company LLP (or its successor), and for the approval of the compensation of the named executive officers.
• The company had 35,381,611 shares of common stock outstanding and entitled to vote as of April 16, 2024, held by 67 stockholders of record.
• A quorum requires a majority of the shares of common stock entitled to vote to be represented at the Annual Meeting, either in person or by proxy.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting necessary information for shareholders. It's generally neutral, with a slight positive leaning due to the board's recommendations and focus on corporate governance.

Positives

• The Board of Directors is actively engaged in corporate governance, with regular meetings and committees overseeing key areas.
• The Audit Committee pre-approves all services provided by the independent registered public accounting firm.
• The company has a Code of Business Conduct and Ethics in place for directors, officers, and employees.
• The Board has a Lead Independent Director to ensure independent oversight and management accountability.
• The Compensation Committee retained Mercer, Inc. as an external compensation consultant to assist in its review of executive and director compensation practices.

Negatives

• Teresa F. Sparks is not standing for re-election, reducing the board size from six to five directors.
• The company's investment in Surface Pharmaceuticals, Inc. was reduced to $0 during the year ended December 31, 2021, as a result of the company recording its share of equity losses of Surface.
• The company's common stock investment in Melt Pharmaceuticals, Inc. was reduced to $0 during the year ended December 31, 2021, as a result of the company recording its share of equity losses in Melt since its deconsolidation in 2019.
• As of the date of termination of the Melt Loan Agreement, approximately $18,395,000 remained outstanding under the Melt Loan Agreement.

Risks

• The proxy statement mentions potential conflicts of interest in related party transactions, requiring ongoing review by the Audit Committee.
• The company's investment in Melt Pharmaceuticals, Inc. is subject to risks, as the company has no other requirements to advance funds to Melt.
• The company's insider trading policy discourages hedging or monetization transactions, which could limit the flexibility of directors and officers in managing their investments.
• The company's success depends on attracting, motivating, and retaining highly skilled executives, and failure to do so could harm the company's performance.

Future Outlook

The company expects to engage the KMJ Successor to serve as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, following the closing of the acquisition of KMJ.

Management Comments

• Mark L. Baum, Chief Executive Officer and Chairman of the Board, cordially invites stockholders to attend the 2024 Annual Meeting.
• The Board believes that the current leadership structure, with Mr. Baum serving as both CEO and Chairman, is the most effective for the company at this time.

Industry Context

The document provides insight into the corporate governance practices and executive compensation strategies of a publicly-traded pharmaceutical company, which is relevant to understanding industry standards and investor expectations.

Comparison to Industry Standards

• The document mentions that the Compensation Committee uses industry data compiled by Mercer in its Global Life Sciences Survey to evaluate executive compensation.
• The Compensation Committee adopted a group of peer companies in 2023, including Agios Pharmaceuticals, Anika Therapeutics, Enanta Pharmaceuticals, Eyepoint Pharmaceuticals, Glaukos Corporation, Heron Therapeutics, IVERIC bio, Inc., Karyopharm Therapeutics, Kodiak Sciences, Nektar Therapeutics, Ocular Therapeutix, RVL Pharmaceuticals, Revance Therapeutics, Rigel Pharmaceuticals, STAAR Surgical Company, and Travere Therapeutics.
• The document mentions that the company's employee benefit plans, including medical, dental, vision, group life, disability and accidental death and dismemberment insurance, are comparable to those provided at peer companies.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a Klarity License Agreement with Richard L. Lindstrom, a former director, requiring royalty payments based on net sales of the Klarity Product.
• The company has an Injectable Asset Purchase Agreement with Richard L. Lindstrom, a former director, requiring royalty payments based on net sales of the Lindstrom Product.
• The company has a Presbyopia Asset Purchase Agreement with Richard L. Lindstrom, a former director, requiring royalty payments based on net sales of the Presbyopia Product.
• The company has investments in Surface Pharmaceuticals, Inc. and Melt Pharmaceuticals, Inc., and has entered into related agreements with these companies.

Stakeholder Impact

• The election of directors will determine the leadership and oversight of the company, impacting shareholders.
• The advisory vote on executive compensation allows shareholders to express their views on the company's pay practices.
• The ratification of the independent registered public accounting firm ensures the integrity of the company's financial reporting, impacting investors and creditors.

Next Steps

• Stockholders are urged to promptly complete the proxy card and return it or use the telephone or Internet voting system.
• The Audit Committee expects to select and engage the KMJ Successor to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, following the closing of the acquisition of KMJ.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, Harrow Inc.